Mobile

A Phase 1b/2 Study of Gemcitabine-Cisplatin, With or Without LY2275796 Sodium, in Patients with Advanced Stage IIIB or IV Non-Small Cell Lung Cancer

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-001535-35

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The Study consists of two parts. The primary objective of Part 1 of the study is to determine a safe dose of LY2275796 in combination with gemcitabine and cisplatin for Part 2. The primary objective of Part 2 of the study is to determine whether the progression-free-survival in patients with advanced (Stage IIIB or IV) NSCLC can be improved by combining LY2275796 with gemcitabine and cisplatin.

Critère d'inclusion

  • Non small cell lung cancer (NSCLC)

Liens